Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
BIIB trades against a final fair-value range of $192.23-$314.03, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Leqembi adoption is stunted by administration bottlenecks or safety concerns while the MS franchise erodes faster than modeled, forcing sustained margin compression and multiple degradation.
Severe administration bottlenecks and ARIA safety concerns permanently stunt Leqembi uptake.
Legacy MS products lose market share far faster than expected, crashing trailing cash flows before pipeline kicks in.
Global structural drug pricing pressures disproportionately target Biogen's high-margin neurology portfolio.
| Khoản mục | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Doanh thu | $10.17B | $9.84B-3.2% | $9.68B-1.6% | $9.89B+2.2% | -0.9% |
| Lợi nhuận gộp | $7.90B | $7.30B | $7.37B | $7.49B | -1.8% |
| Lợi nhuận hoạt động | $2.90B | $1.85B | $2.28B | $2.47B | -5.2% |
| Lợi nhuận ròng | $3.05B | $1.16B-62.0% | $1.63B+40.5% | $1.29B-20.9% | -24.9% |
| EPS (pha loãng) | $20.87 | $7.97 | $11.18 | $8.79 | -25.0% |
| EBITDA | $4.36B | $2.04B | $2.83B | $2.60B | -15.8% |
| R&D | $2.23B | $2.45B | $1.98B | $1.78B | -7.3% |
| SG&A | $2.40B | $2.55B | $2.40B | $2.43B | +0.4% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
